GlobeNewsWire
09 Jun 2026, 16:47 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
Story key points
4 claims · impact-rated
Phase 3 trial data for masitinib in ALS showed a five-year survival rate of 42.3%, significantly exceeding registry benchmarks of approximately 24%. — Strong survival data in a lethal disease with high unmet need is a primary catalyst for drug approval and significant valuation increases for biotech firms.
+0.80Nearly half (49%) of long-term survivors on masitinib maintained a satisfactory quality of life without requiring mechanical assistance. — Clinical efficacy is strengthened when survival is paired with functional independence, increasing the likelihood of regulatory success and market adoption.
+0.50AB Science will present the full survival data from the masitinib clinical program at the ENCALS annual meeting from June 24-26, 2026. — The upcoming presentation creates a specific volatility window and a catalyst event for investors to digest the full dataset.
+0.30Continue reading
6 related stories
The company has identified a biomarker that detects masitinib's effect on pro-inflammatory microglia to help identify responsive patients. — Precision medicine markers reduce trial risk and improve the probability of approval by targeting the most responsive patient cohorts.
+0.20Ticker attribution
Model heads
The company reported phase 3 trial data indicating clinically relevant survival benefits for its lead compound masitinib in ALS patients.
No ticker relationship head found.
Free. No credit card.
Early access
Unlock the full impact breakdown — and whether these names are in a Stage 2 uptrend right now. Free account, 30 seconds.
No credit card. Cancel anytime.
Browse live screeningsImpact vectors
7 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
6h ago
